ADTX
BEARISH
$1.82
Live
Aditxt, Inc. · NASDAQ
$1.76
52W Range
$11679.7
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Mar 14, 2026
Market cap
$0.4M
P/E
N/A
ROE
N/A
Profit margin
N/A
Debt/Equity
N/A
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
95%
ADTX exhibits severe financial distress, reflected in a Piotroski F-Score of 1/9 (indicating weak financial health) and a lack of an Altman Z-Score, which raises significant bankruptcy risk. The company is unprofitable with a negative ROA of -61.70%, a gross margin of 0.00%, and a staggering -419,870.30% operating margin. Revenue has collapsed by 89.10% YoY, and the stock has declined 100% over the past five years. Despite a low price of $1.82, the valuation metrics are nonsensical (e.g., Price/Sales of 67.96, negative P/E), suggesting extreme overvaluation or data failure. The absence of any analyst coverage and negative insider activity further confirm a lack of institutional confidence.
Key Strengths
Minimal market cap may offer speculative appeal for high-risk investors
Recent quarter showed a slight Q/Q EPS improvement (+6.9%)
One quarter beat earnings estimate (1/4), indicating potential for volatility in results
Low price point ($1.82) may attract retail traders seeking deep value
No reported debt (implied by missing Debt/Equity) reduces leverage risk
Key Risks
Piotroski F-Score of 1/9 indicates extreme financial weakness and poor operational efficiency
Negative ROA (-61.70%) and operating margin (-419,870.30%) signal severe profitability collapse
Revenue declined 89.10% YoY, with inconsistent and erratic earnings surprises (avg -96.38%)
Current and quick ratios of 0.02 indicate near-total inability to meet short-term obligations
Insider selling (2 transactions) with no buys signals lack of confidence from within the company
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
7
Weak
10
10
10
5
0
AI Verdict
High Risk - Unstable
Key drivers: Piotroski F-Score of 1/9, Negative operating and ROA metrics, 90%+ revenue decline, Insider selling, No analyst coverage
Confidence
95%
Value
10/100
Ref P/E, PEG, Graham Number
Positives
- Low nominal price ($1.82) may appeal to speculative investors
Watchpoints
- Price/Sales of 67.96 is extremely high for a loss-making company
- No Graham Number or intrinsic value available
- Negative P/E and PEG ratios render traditional valuation models inapplicable
- Market cap is effectively $0.00B, suggesting no real market value
Future
10/100
Ref Growth rates
Positives
- Slight Q/Q EPS improvement (+6.9%) in most recent quarter
Watchpoints
- Revenue growth is -89.10% YoY
- Earnings surprises are consistently negative (avg -96.38%)
- No analyst target prices or consensus, indicating lack of market interest
- No forward guidance or growth indicators
Past
10/100
Ref Historical trends
Positives
- One quarter (2023-04-17) beat estimates with a +310.8% surprise
Watchpoints
- Three of four quarters missed estimates by large margins
- Earnings volatility is extreme (surprise range: -511.1% to +310.8%)
- 5-year, 3-year, and 1-year returns are all -100%
- Price dropped from $11,679.68 to $1.82, indicating catastrophic decline
Health
5/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- No reported debt (implied by missing Debt/Equity)
- Low current and quick ratios may reflect minimal short-term liabilities
Watchpoints
- Piotroski F-Score of 1/9 indicates severe financial deterioration
- Current ratio of 0.02 suggests inability to cover short-term liabilities
- Operating margin of -419,870.30% is unsustainable
- No Altman Z-Score available, but the financials suggest distress risk
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout ratio
- Dividend strength is 0/100
- Company is unprofitable and likely cannot afford dividends
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$1.82
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ADTX and closest competitors.
Updated 2026-03-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ADTX
Aditxt, Inc.
Primary
|
-100.0% | -100.0% | -100.0% | -99.8% | -67.1% | -51.2% |
|
AKAN
Akanda Corp.
Peer
|
-100.0% | -100.0% | -96.4% | -95.4% | -13.6% | -6.7% |
|
BDRX
Biodexa Pharmaceuticals Plc
Peer
|
-100.0% | -100.0% | -95.1% | -75.6% | -24.0% | -4.0% |
|
IMCC
IM Cannabis Corp.
Peer
|
-99.9% | -91.4% | -72.7% | -81.3% | -57.0% | +6.5% |
|
INM
InMed Pharmaceuticals Inc.
Peer
|
-100.0% | -97.1% | -71.7% | -66.3% | -10.5% | +5.6% |
ADT
Aditxt, Inc.
Primary
5Y
-100.0%
3Y
-100.0%
1Y
-100.0%
6M
-99.8%
1M
-67.1%
1W
-51.2%
AKA
Akanda Corp.
Peer
5Y
-100.0%
3Y
-100.0%
1Y
-96.4%
6M
-95.4%
1M
-13.6%
1W
-6.7%
BDR
Biodexa Pharmaceuticals Plc
Peer
5Y
-100.0%
3Y
-100.0%
1Y
-95.1%
6M
-75.6%
1M
-24.0%
1W
-4.0%
IMC
IM Cannabis Corp.
Peer
5Y
-99.9%
3Y
-91.4%
1Y
-72.7%
6M
-81.3%
1M
-57.0%
1W
+6.5%
INM
InMed Pharmaceuticals Inc.
Peer
5Y
-100.0%
3Y
-97.1%
1Y
-71.7%
6M
-66.3%
1M
-10.5%
1W
+5.6%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-0.16
PEG Ratio
N/A
P/B Ratio
-0.01
P/S Ratio
67.96
EV/Revenue
758.92
EV/EBITDA
-0.22
Market Cap
$0.4M
Profitability
Profit margins and return metrics
Profit Margin
N/A
Operating Margin
-419870.0%
Gross Margin
N/A
ROE
N/A
ROA
-61.7%
Growth
Revenue and earnings growth rates
Revenue Growth
-89.1%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
N/A
Current Ratio
0.02
Weak
Quick Ratio
0.02
Poor
Cash/Share
$2.33
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q3 2025
Revenue
$0.0B
Gross Margin
2.1%
Op. Margin
-419870.3%
Net Margin
-3214626.3%
Total Assets
$0.0B
Liabilities
$0.0B
Equity
$-0.0B
Debt/Equity
-2.67x
Operating CF
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
100%
Quarterly Earnings History
EPS performance vs analyst estimates
2023-11-14
$-440878683.78
-511.1% surprise
2023-05-15
$-473693726.27
-48.9% surprise
2023-04-17
$1128186584.7
+310.8% surprise
2022-11-14
$-1905622853.01
-136.3% surprise
Healthcare Sector Comparison
Comparing ADTX against 291 companies in the Healthcare sector
(20 bullish, 99 neutral, 172 bearish)
Revenue Growth
-89.1%
This Stock
vs
80.78%
Sector Avg
-210.3%
(Slower)
Current Ratio
0.02
This Stock
vs
3.72
Sector Avg
-99.5%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ADTX
Aditxt, Inc.
|
BEARISH | $0.4M | - | -% | -% | $1.82 | |
|
AKAN
Akanda Corp.
|
BEARISH | $1.73M | 0.01 | -60.9% | -266.3% | $0.82 | Compare |
|
BDRX
Biodexa Pharmaceuticals Plc
|
BEARISH | $1.8M | - | -61.8% | -% | $2.15 | Compare |
|
IMCC
IM Cannabis Corp.
|
BEARISH | $2.25M | - | -% | -20.7% | $0.36 | Compare |
|
INM
InMed Pharmaceuticals Inc.
|
BEARISH | $2.37M | - | -97.2% | -170.1% | $0.72 | Compare |
ADTX
Aditxt, Inc.
BEARISH
Mkt Cap
$0M
P/E
-
ROE
-%
Price
$1.82
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-12-17 | BRADY BRIAN MICHAEL | Director | Sale | 1 | $2 |
| 2025-11-25 | PANKOVCIN CORINNE D | Officer | Sale | 1 | $3 |
BRADY BRIAN MICHAEL
Director
2025-12-17
1 shares
·
$2
PANKOVCIN CORINNE D
Officer
2025-11-25
1 shares
·
$3
Insider transactions can signal confidence or concerns about company prospects
Past News Coverage
Recent headlines mentioning ADTX from our newsroom.
Newest → oldest
No matching news yet.